Thrombocytopenia and nausea were the most common hematological and non-hematological adverse events, respectively.<h4>Conclusion</h4>This meta-analysis demonstrated that HDAC inhibitors were effective treatment options for untreated and R/R PTCL patients. This evidence concerns the gene HDAC9 and mature T-cell and NK-cell non-Hodgkin lymphoma.